Device
Alfapump
Alfapump is a medical device with 6 clinical trials. Currently 1 active trials ongoing. Historical success rate of 33.3%.
Total Trials
6
Max Phase
—
Type
DEVICE
Molecule
—
Success Metrics
Clinical Success Rate
33.3%
Based on 1 completed trials
Completion Rate
33%(1/3)
Active Trials
1(17%)
Results Posted
0%(0 trials)
Terminated
2(33%)
Phase Distribution
Ph not_applicable
3
50%
Ph phase_1
1
17%
Phase Distribution
1
Early Stage
0
Mid Stage
0
Late Stage
Phase Distribution4 total trials
Phase 1Safety & dosage
1(25.0%)
N/ANon-phased studies
3(75.0%)
Highest Phase Reached
Phase 1Trial Status & Enrollment
Completion Rate
25.0%
1 of 4 finished
Non-Completion Rate
75.0%
3 ended early
Currently Active
1
trials recruiting
Total Trials
6
all time
Status Distribution
Active(1)
Completed(1)
Terminated(3)
Other(1)
Detailed Status
Terminated2
Withdrawn1
Completed1
Active, not recruiting1
unknown1
Development Timeline
Analytics
Development Status
Total Trials
6
Active
1
Success Rate
33.3%
Most Advanced
Phase 1
Trials by Phase
Phase 11 (25.0%)
N/A3 (75.0%)
Trials by Status
withdrawn117%
completed117%
terminated233%
active_not_recruiting117%
unknown117%
Recent Activity
1 active trials
Showing 5 of 6
active_not_recruiting
International Alfapump Cohort Study
NCT04326946
unknownnot_applicable
Alfapump® System in the Treatment of Refractory or Recurrent Ascites (POSEIDON Study)
NCT03973866
withdrawnphase_1
Optimal Balance Alfapump® System Feasibility Study
NCT03032211
terminatednot_applicable
Alfapump System Versus Transjugular Intrahepatic Portosystemic Shunt and Paracentesis in the Treatment of Ascites
NCT02612519
completed
Retrospective Study in the Use of the Alfapump and the Treatment of Malignant Ascites
NCT03200106
Clinical Trials (6)
Showing 6 of 6 trials
NCT04326946
International Alfapump Cohort Study
NCT03973866Not Applicable
Alfapump® System in the Treatment of Refractory or Recurrent Ascites (POSEIDON Study)
NCT03032211Phase 1
Optimal Balance Alfapump® System Feasibility Study
NCT02612519Not Applicable
Alfapump System Versus Transjugular Intrahepatic Portosystemic Shunt and Paracentesis in the Treatment of Ascites
NCT03200106
Retrospective Study in the Use of the Alfapump and the Treatment of Malignant Ascites
NCT02448160Not Applicable
Alfapump-albumin Replacement Therapy
All 6 trials loaded
Drug Details
- Intervention Type
- DEVICE
- Total Trials
- 6